Related Experiment Video
Updated: Mar 31, 2026
08:59
Real-Time Fluorescent Measurement of Synaptic Functions in Models of Amyotrophic Lateral Sclerosis
Published on: July 16, 2021
3.2K
Purinergic contribution to amyotrophic lateral sclerosis
Cinzia Volonté1, Savina Apolloni2, Chiara Parisi3
1Institute of Cell Biology and Neurobiology, CNR, Rome, Italy; Fondazione Santa Lucia, IRCCS, Rome, Italy.
Neuropharmacology
|October 31, 2015
Summary
Extracellular purinergic signaling, involving P2X and P2Y receptors, plays a key role in the nervous system. Dysregulation is linked to neurodegenerative diseases like amyotrophic lateral sclerosis (ALS), prompting new research directions.
Area of Science:
- Neuroscience
- Molecular Biology
- Cell Biology
Background:
- Extracellular nucleotides signal through purinergic receptors (P1, P2X, P2Y), influencing nervous system function.
- Dysregulation of purinergic signaling is implicated in neurodegenerative and neuroinflammatory diseases.
- Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease characterized by motoneuron loss.
Purpose of the Study:
- To investigate the role of purinergic signaling in amyotrophic lateral sclerosis (ALS).
- To explore the contribution of specific purinergic receptors (P2X4, P2X7, P2Y6) in ALS pathogenesis.
- To review the progression of purinergic signaling research in ALS towards preclinical applications.
Main Methods:
- Analysis of P2X4, P2X7, and P2Y6 receptor expression in ALS animal and cell models, and human patient tissues.
- In vitro studies on purinergic signaling in microglia, astrocytes, and motoneurons.
- Review of existing literature and preclinical trial data on purinergic signaling in ALS.
Main Results:
- P2X4, P2X7, and P2Y6 receptor expression is altered in ALS models and patients.
- Purinergic signaling pathways in glial cells and motoneurons are significantly affected in ALS.
- Research on purinergic signaling in ALS has advanced to preclinical stages.
Conclusions:
- Purinergic signaling is a critical factor in the pathogenesis of ALS.
- Targeting purinergic pathways offers potential therapeutic strategies for ALS.
- Further investigation into purinergic signaling is warranted for ALS treatment development.
Related Concept Videos
03:03Amyloid Fibrils
13.0K
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
13.0K
01:22Lysosomal Hydrolases
4.7K
Lysosomes are the site for the degradation of macromolecules and biological polymers released during membrane trafficking events such as secretory, endocytic, autophagic, and phagocytic pathways. The membrane-enclosed area of the lysosome, called the lumen, contains hydrolytic enzymes active in an acidic environment. These acid hydrolases are functional at a pH between 4.5 and 5 and are involved in cellular processes such as cell signaling, energy metabolism, restoration of the plasma membrane,...
4.7K
01:15Parkinson's Disease: Overview
2.4K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
2.4K